MELVILLE, N.Y.--(BUSINESS WIRE)--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that results published yesterday in the Journal of Clinical Oncology show that adding Tarceva® (erlotinib) to gemcitabine chemotherapy significantly improves survival when administered as first-line therapy to patients with advanced pancreatic cancer. Data from this study, conducted by the National Cancer Institute of Canada (NCIC), formed the basis of both the U.S. and European approvals for Tarceva in this patient population.
